Recurring software revenue and a flagship US customer rollout reshape what FY27 earnings should look like
Austco Healthcare (ASX:AHC) has handed investors a FY26 trading update that does two things at once. It confirms a strong financial year, and it points to a much bigger US story that will play out across the 2026 calendar year.
Revenue is guided to A$90 million to A$95 million, up between 11% and 17% on FY25. Net profit after tax is expected at A$9.0 million to A$9.4 million, up between 52% and 58%. Gross margin nudges up to around 52.8% from 52.0%.
- Updated
- INSIDER CONVICTION TRADES FY26
The market hasn't noticed yet.
Disclosed by law. Missed by most investors. 129 trades tracked by us.
NO Credit card
- Director buys & sells tracked
- Buy / Hold / Sell verdict on every stock
- Technical analysis included
The headline number is the NPAT jump, but the operationally interesting line is buried further down. Austco’s largest US customer has contracted to roll out Pulse Mobile, its clinical communication product, across roughly 180 hospitals during the 2026 calendar year.
That single rollout reframes the FY27 setup for a company that supplies nurse call and clinical workflow technology to hospitals globally. We think it deserves more attention than it will probably get on the day of release.
The 52% NPAT jump has a one-off helper sitting inside it
It is worth noting upfront that Austco’s forecast NPAT uplift includes a one-off benefit of around A$1.0 million from the reduction of G&S contingent consideration recognised in prior periods. Strip that out and underlying NPAT growth is closer to 35% to 40%, still respectable but not the headline 52% to 58%.
The gross margin expansion to 52.8% is the cleaner signal. That 80 basis point lift reflects the growing contribution of recurring software and maintenance revenue from the Tacera platform, Austco’s IP nurse call system. Hardware businesses do not move gross margins like this without a meaningful shift in revenue mix.
Austco’s EBITDA margin actually compressed slightly from 16.0% to about 15.5%, with management flagging continued investment in people and capability. We would rather see margin reinvested into US capability than harvested early.
Why the Pulse Mobile rollout is the line that matters
Austco already had a relationship with this US customer. The new agreement deepens it into a network-wide deployment of clinical communication software across approximately 180 hospitals. That is not a pilot. That is a customer betting its mobile clinical workflow on Austco’s product.
The financial implications run beyond the initial deployment revenue. Pulse Mobile sits on top of Tacera and generates ongoing software and maintenance income tied to user count and facility licences. A 180-hospital footprint creates a recurring revenue base that should compound through FY27 and beyond.
It also acts as a reference deployment. Selling clinical communication software into US hospital systems is notoriously slow, but a network-wide rollout at this scale gives Austco’s sales team a credibility lever it did not have before.
Second-half headwinds tell us where the real risks sit
Management has been candid that second-half trading was tougher. Longer freight transit times, extended lead times on electronic components due to AI-driven semiconductor demand, and slower construction programs in certain regions all pushed some installations into later periods.
The framing is that this is timing rather than lost revenue, and the contract wins back that up. G&S in New Zealand landed an NZ$1.1 million retirement and aged care portfolio, Warrnambool Hospital came in at around A$1.1 million in Victoria, and North York General in Canada added another A$0.9 million.
The skeptical read is that supply chain and construction timing risk does not vanish in FY27. Investors should expect this to keep showing up as quarterly noise even if the full-year numbers land cleanly.
The Investors Takeaway for Austco Healthcare
Austco has delivered a FY26 update that is genuinely strong even after stripping out the one-off benefit. Revenue growth, expanding gross margin, and a deepening recurring revenue base put the company in a different category from a pure hardware vendor.
If the Pulse Mobile deployment progresses on schedule through the 2026 calendar year, the recurring revenue tail and the reference-customer effect could meaningfully change how the market values this business. Investors looking for more in-depth coverage of ASX healthcare technology names can find it at stocksdownunder.
We would want to see the FY26 audited result confirm the gross margin expansion, and H1 FY27 numbers show early Pulse Mobile revenue feeding through. Those are the two checkpoints that decide whether this update marks a genuine step change.
